APLIF
Appili Therapeutics Inc.·Healthcare
0.01
0.307%(−0.00)
Close PriceLast Updated: — ET
52W L: $0.0152W H: $0.03
APLIF NEWS
globenewswire.com
Mar 30
Appili Therapeutics to Exhibit at World Vaccine Congress Washington
Appili Presentation Highlights Recent Collaborations and Funding Milestones Appili Executives to Conduct In-Person Meetings and in Washington, D.C. to Identify New Funding Opportunities HALIFAX, Nova Scotia, March 30, 2026 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced that President and Chief Executive Officer Dr. Don Cilla and Chief Development Officer, Dr. Gary Nabors will exhibit at the World Vaccine Congress Washington 2026.
globenewswire.com
Feb 18
Appili Therapeutics Announces Closing of Second Tranche of Non-Brokered Private Placement
NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. WIRE SERVICES HALIFAX, Nova Scotia, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, is pleased to announce that it has closed the second tranche of its previously announced non-brokered private placement for aggregate gross proceeds of C$100,000 (the “Private Placement”). The Private Placement consisted of the issuance and sale of 4,000,000 units of the Company (the “Units”) at a price of C$0.025 per Unit.
globenewswire.com
Feb 12
Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2026
US$82 Million in Pending Proposals Across Multiple Infectious Disease Programs US$40 Million NIAID Funding Award Supports VXV-01 Development Through Phase 1 LIKMEZ® (ATI-1501) Commercial Momentum with Increased U.S. Market Adoption HALIFAX, Nova Scotia, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX:APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced its financial and operational results for the third quarter of its fiscal year 2026, which ended on December 31, 2025. All figures are in Canadian dollars unless otherwise stated.
